P2‐163: Performance Evaluation of New Absorbance‐Based Elisas for Measuring Different Alpha‐Synuclein (A‐SYN) Species in CSF and Plasma

Stoops, Erik; Majbour, Nour K.; Mauroo, Kimberley; Demeyer, Leentje; Lashuel, Hilal A.; Trojanowski, John Q.; Lee, Virginia M.‐Y.; Agnaf, Omar El; Vanderstichele, Hugo

doi:10.1016/j.jalz.2016.06.1330

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FABP3, Aβ 1–42 , total tau (t-tau), and p-tau were measured using commercially available enzyme-linked immunosorbent assays (ELISAs) (FABP3 Human ELISA, Hycult Biotech, Uden, The Netherlands; INNOTEST β-AMYLOID(1–42)™, Fujirebio Europe, Gent, Belgium; Total Tau ELISA, Phosphorylated Tau 181 ELISA, EUROIMMUN AG, Lübeck, Germany) and according to previous reports [ 38 , 39 ]. α-Syn was measured at ADx NeuroSciences (Gent, Belgium) using a new assay developed internally [ 40 ]. The ADx α-syn research ELISA is a colorimetry-based sandwich immunoassay (96-well microplate format) with a readout that can be measured in a conventional microplate reader using a 450-nm filter.…”

Section: Methodsmentioning

confidence: 99%

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundNeurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease with dementia (PDD), and dementia with Lewy bodies (DLB) share clinical and molecular features. Cerebrospinal fluid (CSF) biomarkers may help the characterization of these diseases, improving the differential diagnosis. We evaluated the diagnostic performance of five CSF biomarkers across a well-characterized cohort of patients diagnosed with AD, DLB, PDD, and Parkinson’s disease (PD).MethodsA total of 208 patients were enrolled in 3 European centers. The diagnostic groups (AD, n = 48; DLB, n = 40; PDD, n = 20; PD, n = 54) were compared with cognitively healthy neurological control subjects (patients with other neurological diseases [OND], n = 46). CSF levels of fatty acid binding protein 3, heart type (FABP3), α-synuclein (α-syn), amyloid-β peptide 1–42, total tau (t-tau), and phosphorylated tau 181 (p-tau) were assessed with immunoassays. Univariate and multivariate statistical analyses were applied to calculate the diagnostic value of the biomarkers as well as their association with clinical scores.ResultsFABP3 levels were significantly increased in patients with AD and DLB compared with those with PD and OND (p < 0.001). CSF t-tau, p-tau, and α-syn were significantly higher in patients with AD than in patients with PDD, DLB, PD, and OND. Combination of FABP3 with p-tau showed high accuracy for the differential diagnosis between AD and DLB (AUC 0.92), whereas patients with AD were separated from those with PDD using a combination of p-tau, FABP3, and α-syn (AUC 0.96). CSF FABP3 was inversely associated with Mini Mental State Examination score in the whole cohort (r = −0.42, p < 0.001).ConclusionsThe combination of CSF biomarkers linked to different aspects of neurodegeneration, such as FABP3, α-syn, and AD biomarkers, improves the biochemical characterization of AD and Lewy body disorders.Electronic supplementary materialThe online version of this article (doi:10.1186/s13195-017-0276-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%